Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
Conditions
- Non Small Cell Lung Cancer
Interventions
- DRUG: Anlotinib Plus Icotinib
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Collaborators